Key Takeaways:
ARS Pharmaceuticals Inc. faces a securities class action over neffy coverage timing as SPRY shares fell 23.9% in one session. The lawsuit, filed on behalf of investors who purchased securities between March 9 and June 24, 2026, alleges the company misled the market about the expected timeline for expanded CVS Caremark insurance coverage for its needle-free epinephrine nasal spray.
"Individual officers who speak to investors about the status of commercial negotiations bear responsibility for the accuracy of those characterizations," Joseph E. Levi, founding partner at Levi & Korsinsky, said. "The complaint alleges statements describing the CVS Caremark process as nearing completion were made without disclosing the risk of a delay into January 2027."
ARS shares closed at $10.54 on June 24, then fell $2.52, or 23.9%, to $8.02 the following session on roughly 99.3 million shares outstanding. The drop followed the company's disclosure that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark reserved its decision until January 2027.
The lawsuit adds legal and reputational pressure on ARS Pharmaceuticals as it seeks to commercialize neffy, its only marketed product. The delayed CVS Caremark decision pushes potential expanded coverage past the summer and back-to-school allergy seasons, a critical revenue window for the company.
Eric Karas, the company's chief commercial officer, is named as an individual defendant. The complaint identifies him as a speaker on the March 9 and May 15 earnings calls, where he told investors the company was "highly focused on CVS Caremark, Anthem and the large regional payers to ensure commercial coverage without restrictions." On March 9, he cited approximately 93 percent overall commercial coverage with roughly 57 percent of covered lives accessing neffy without prior authorization, and approval rates near 55 percent where prior authorization applied. On May 15, he stated the CVS Caremark proposal was "in the final stages of the approval process" and that the payer process was "nearing completion."
The lead plaintiff deadline is October 5, 2026. Under the Private Securities Litigation Reform Act, the court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought who is adequate and typical of class members. Investors who purchased during the class period may also participate in any recovery without seeking lead plaintiff appointment.
Multiple law firms are investigating the case, including Faruqi & Faruqi, Levi & Korsinsky, and Schall Brown & Schwartz. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Investors will watch for any settlement announcements or additional disclosures from the company before the October 5 lead plaintiff deadline. The outcome of the litigation could affect ARS Pharmaceuticals' ability to secure future partnerships or funding for neffy commercialization.
This article is for informational purposes only and does not constitute investment advice.
